 Sometimes it pays for investors to take a contrarian approach, moving in the opposite direction of the prevailing sentiment surrounding a stock. After all, the Oracle of Omaha himself, Warren Buffett, famously said, "Be fearful when others are greedy and greedy when others are fearful." This may .... |
Good MorningDespite headlines declaring the AI bubble has popped, recent data says otherwise. Micron's massive earnings beat and bullish guidance, fueled by demand for high-bandwidth memory, highlight ongoing investment in AI infrastructure. Institutional accumulation and analyst upgrades across NVIDIA-adjacent names confirm smart money is still buying. Add in cooling inflation, expected Fed rate cuts, and a solid consumer backdrop, and the setup for 2026 remains strong.
The S&P 500 is consolidating near highs and looks ready to rally into year-end. December's tight trading range has reset key technical indicators just as Q4 earnings season approaches. Labor data remains firm, retail sales are solid, and earnings forecasts are rising across upcoming quarters. With JPMorgan reporting in just three weeks and momentum building, the market could easily break out in a classic Santa Claus Rally. Featured: 5 Stocks Benefiting from the New Administration (Ad) 
| Finance | | | Sometimes it pays for investors to take a contrarian approach, moving in the opposite direction of the prevailing sentiment surrounding a stock. After all, the Oracle of Omaha himself, Warren Buffett, famously said, "Be fearful when others are greedy and greedy when others are fearful." This may ... Read the Full Story |
| From Our Partners | | 2026 is already shaping up to be a pivotal year.
Interest rates are stabilizing, inflation pressures are easing, and investors are rethinking how to position for the next cycle.
That's why veteran analyst Jim Archer just released his latest Buy & Hold Blueprint — a free educational report revealing one data-backed stock he believes every long-term investor should know this year. | | 👉 [Click here to read the full 2026 Buy & Hold Blueprint] |
| Finance | | | The northeast United States wasn’t the only region gripped by bitter cold this month—a new winter has also hit the cryptocurrency market. Weak sentiment and choppy trading threaten Bitcoin with its worst yearly performance since 2022. What’s caused the cryptocurrency stallout in ... Read the Full Story |
| Transportation | | | A single analyst's rating and price target, the consensus rating and price target, for that matter, have little value to investors without the proper context. The context is the sentiment strength and trend, which for stocks like PepsiCo (NASDAQ: PEP), AbbVie (NYSE: ABBV), and United Parcel Servic... Read the Full Story |
| | Finance | | | While artificial intelligence (AI) has dominated headlines for much of the year, and sent many tech stocks soaring, some of the strongest performance across equities has come from far less glamorous corners. Bank stocks are in the middle of a standout run, with the Financial Select Sector SPDR ETF... Read the Full Story |
| Construction | | | The S&P 500 Index is indisputably the most referenced benchmark for tracking the performance of large-cap U.S. stocks. Each quarter, the S&P 500 Index Committee (a committee within S&P Dow Jones Indices) reassesses which stocks will or will not remain in the index. This typically resul... Read the Full Story |
| From Our Partners | | Elon Musk's Starlink project is generating major speculation ahead of a potential IPO that some analysts believe could reach a historic $100 billion valuation. According to James Altucher, there may be a smart "backdoor" way for everyday investors to position ahead of that event without needing traditional IPO access — and he says it can be done for under $100. He's also sharing a free ticker tied to this trend for anyone who wants to take a closer look. | | Click here to learn more |
| Markets | | | After finishing 2024 with the third-best performance of the S&P 500’s 100 sectors, the financial sector is wrapping up 2025 with strong momentum that could carry into 2026. Over the past month, the sector has risen 4.18%. And after the Federal Reserve enacted its third and final interes... Read the Full Story |
| Consumer Discretionary | | | The last three years have not been kind to U.S. apparel giant Nike (NYSE: NKE). As of the Dec. 18 close, shares had dropped approximately 34%, with sales, margins, and profits all down significantly over the same period. A series of strategic missteps contributed to this, including weak product... Read the Full Story |
| Utilities | | | As 2025 winds down, tech investors are facing a familiar mix of excitement and anxiety. With AI stock valuations at historic highs, the question heading into 2026 is no longer whether AI is transformative—but whether the market has gotten ahead of itself. Recent news also contributed to som... Read the Full Story |
| Markets | | | Hundreds of exchange-traded funds (ETFs) launched in the last year alone, further crowding an already-dense field and making it more difficult for investors to assess which might be a good fit for their portfolios. Many ETF investors focus on a long-term strategy with these investments—easy... Read the Full Story |
| Technology | | | The last few months of 2025 haven’t brought what investors in Meta Platforms (NASDAQ: META) hoped for. Through late October, shares were up around 28% on the year. Since then, the stock has given back around half those gains, and is now up only 14% (as of the Dec. 18 close). However, inve... Read the Full Story |
| Monday's Early Bird Stock Of The Day Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.... | Should I Buy Gilead Sciences Stock? GILD Bull and Bear Case Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Thursday, December 18, 2025 at 6:34 PM. Gilead Sciences Bull Case - The current stock price is around $120.40, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
- Gilead Sciences, Inc. has received multiple upgrades from analysts, with a consensus target price of approximately $131.13, indicating potential for price appreciation.
- The company reported strong quarterly earnings, exceeding analyst expectations with a revenue of $7.77 billion, showcasing its robust financial performance.
- Gilead Sciences, Inc. has a solid return on equity of 51.86%, reflecting effective management and profitability, which can be attractive to investors.
- With a P/E ratio of 18.67, the stock may be considered reasonably valued compared to its earnings, suggesting it could be a good investment relative to its earnings potential.
Gilead Sciences Bear Case - Insider selling has been notable, with executives selling over 135,000 shares recently, which could signal a lack of confidence in the stock's short-term performance.
- The stock has experienced a decline of about 2.3% recently, which may indicate volatility and potential challenges in maintaining its price level.
- Despite strong earnings, the company faces competition in the biopharmaceutical market, which could impact future growth and profitability.
- The debt-to-equity ratio stands at 1.03, suggesting that the company has a significant amount of debt relative to its equity, which could pose risks in economic downturns.
- Analysts have mixed ratings, with some holding a "Hold" rating, indicating uncertainty about the stock's future performance.
| | View Today's Stock Pick |
|
| |
|
|
